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Background
The soluble pattern-recognition receptor known as long pentraxin 3 (PTX3) has a 
nonredundant role in antifungal immunity. The contribution of single-nucleotide 
polymorphisms (SNPs) in PTX3 to the development of invasive aspergillosis is 
unknown.
Methods
We screened an initial cohort of 268 patients undergoing hematopoietic stem-cell 
transplantation (HSCT) and their donors for PTX3 SNPs modifying the risk of inva-
sive aspergillosis. The analysis was also performed in a multicenter study involving 
107 patients with invasive aspergillosis and 223 matched controls. The functional 
consequences of PTX3 SNPs were investigated in vitro and in lung specimens from 
transplant recipients.
Results
Receipt of a transplant from a donor with a homozygous haplotype (h2/h2) in PTX3 
was associated with an increased risk of infection, in both the discovery study 
(cumulative incidence, 37% vs. 15%; adjusted hazard ratio, 3.08; P = 0.003) and the 
confirmation study (adjusted odds ratio, 2.78; P = 0.03), as well as with defective 
expression of PTX3. Functionally, PTX3 deficiency in h2/h2 neutrophils, presum-
ably due to messenger RNA instability, led to impaired phagocytosis and clearance 
of the fungus.
Conclusions
Genetic deficiency of PTX3 affects the antifungal capacity of neutrophils and may 
contribute to the risk of invasive aspergillosis in patients treated with HSCT. 
(Funded by the European Society of Clinical Microbiology and Infectious Diseases 
and others.)
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Long pentraxin 3 (PTX3) is a soluble pattern-recognition receptor produced by phagocytes and nonimmune cells at sites 
of inflammation or injury. In addition to its ma-
jor role in female fertility and vascular biology,1 
PTX3 has a nonredundant role in modulating 
various effector pathways involved in immune 
resistance to Aspergillus fumigatus, including acti-
vating innate immune cells2 and driving protec-
tive adaptive immunity.3 PTX3 forms complexes 
on the conidial surface of the fungus and acts as 
an opsonin, enhancing recognition and phago-
cytosis of conidia through mechanisms that de-
pend on Fcγ receptor, CD11b, and complement.4 
The interaction of PTX3 with the yeast phase of 
Candida albicans5 and Paracoccidioides brasiliensis6 has 
also been reported.
Mononuclear phagocytes and dendritic cells 
synthesize PTX3 de novo in response to micro-
bial moieties or inflammatory signals. In con-
trast, PTX3 is stored in a ready-made form in 
granules from mature polymorphonuclear leuko-
cytes, and its secretion and localization to extra-
cellular traps promote the control of A. fumigatus 
infection in vivo.7 Therefore, it is not surprising 
that Ptx3 deficiency renders mice susceptible to 
pulmonary aspergillosis because of the defective 
recognition of conidia by neutrophils, alveolar 
macrophages, and dendritic cells.3,4 The suscep-
tibility phenotype is associated with impaired 
activation of a protective type 1 helper T-cell (Th1) 
antifungal response coupled with a detrimental 
type 2 helper T-cell response.3 The administra-
tion of exogenous Ptx3 in mice that have under-
gone bone marrow transplantation reverts the 
susceptibility to disease by restoring the Th1 
response3; the administration of exogenous Ptx3 
also restrains the type 17 helper T-cell response 
and associated pathogenic inflammation induced 
during infection in experimental models of 
chronic granulomatous disease.8 The protective 
effect of exogenous Ptx3 is further substantiated 
by the capacity of the protein to improve the ef-
ficacy of antifungal therapy in mice when the 
two treatments are administered in combina-
tion.9,10
The pivotal role of PTX3 in innate antifungal 
immunity11 makes the protein an attractive can-
didate for studies of genetic susceptibility to 
fungal diseases in high-risk patients, such as 
those undergoing hematopoietic stem-cell trans-
plantation (HSCT). Invasive aspergillosis may 
develop as a complication in 5 to 15% of patients 
undergoing allogeneic HSCT.12-14 We screened 
patients undergoing HSCT and their donors for 
single-nucleotide polymorphisms (SNPs) in the 
PTX3 gene and assessed the association of identi-
fied SNPs with susceptibility to invasive aspergil-
losis and impaired innate antifungal immunity.
Me thods
Patients and Study Procedures
All adult patients with hematologic disorders who 
were undergoing allogeneic HSCT at the Hospital 
of the University of Perugia, in Perugia, Italy, be-
tween 2003 and 2011, and their respective donors 
(who were related in 98% of cases), were eligible 
for the discovery study. Among 430 transplanta-
tions performed in this period, 346 recipient–
donor pairs with available DNA and patient-level 
data were identified. Exclusion criteria were par-
ticipation in clinical studies (64 patients),15 in-
fection with invasive molds other than aspergil-
lus species (12), and pretransplantation infection 
with molds (2). Fifty-one cases of invasive asper-
gillosis were classified as “probable” (in 26 pa-
tients) or “proven” (in 25 patients), according to 
the revised standard criteria from the European 
Organization for Research and Treatment of 
Cancer–Mycoses Study Group16 (Table 1). Among 
these cases, 9 (18%) occurred in the neutropenic 
period and 42 (82%) after engraftment. Transplan-
tation procedures were performed as previously 
described.17 Graft-versus-host disease (GVHD) 
and cytomegalovirus disease were diagnosed ac-
cording to standard criteria.18,19 Conditioning 
regimens and prophylaxis are described in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org. The study was 
approved by the Umbria Regional Hospital Ethics 
Committee in Perugia, and patients and donors 
provided informed written consent for data col-
lection, DNA and cell storage, and their use for 
diagnostic and research purposes.
The methods used for the confirmation study 
(Table S1 in the Supplementary Appendix) and 
the genetic and functional analyses are detailed 
in the Supplementary Appendix.
Statistical Analysis
In the analysis of the discovery data set, the 
probability of invasive aspergillosis according to 
PTX3 variants was determined with the use of the 
PTX3 Deficiency and Aspergillosis
n engl j med 370;5 nejm.org january 30, 2014 423
Table 1. Characteristics of Transplant Recipients in the Discovery Study.*
Clinical Variable
Invasive 
Aspergillosis 
(N = 51)
No Invasive 
Aspergillosis 
(N = 217) P Value†
Age at transplantation — no. (%)
<40 yr 26 (51) 112 (52)
≥40 yr 25 (49) 105 (48) 1.00
Sex — no. (%)
Male 23 (45) 107 (49)
Female 28 (55) 110 (51) 0.64
Sex of donor–recipient pair — no. (%)
Female–male 10 (20) 58 (27)
Other 41 (80) 159 (73) 0.37
Transplantation type — no. (%)
Transplant from HLA-matched related donor 14 (27) 90 (42)
Transplant from HLA-mismatched related donor‡ 37 (73) 122 (56) 0.06
Transplant from HLA-matched unrelated donor 0 5 (2) 0.62
Transplant from HLA-mismatched unrelated donor 0 0 1.00
Underlying disease — no. (%)
Acute leukemia 31 (61) 152 (70)
Lymphoma or myeloma 14 (27) 53 (24) 0.58
Chronic leukemia 4 (8) 11 (5) 0.48
Other 2 (4) 1 (1) 0.08
Disease stage — no. (%)
First complete remission 14 (27) 73 (34)
Second or subsequent remission, or relapse 37 (73) 144 (66) 0.41
Myeloablative conditioning regimen — no. (%)
Total-body irradiation 43 (84) 150 (69)
No total-body irradiation 8 (16) 67 (31) 0.04
CMV serostatus of donor and recipient — no. (%)
Donor and recipient CMV-negative or donor CMV-positive 
and recipient CMV-negative
5 (10) 27 (12)
Donor CMV-negative and recipient CMV-positive or donor 
and recipient CMV-positive 
46 (90) 190 (88) 0.65
Duration of neutropenia — median no. of days (range)§ 16 (10–24) 16 (10–40) 0.39
Acute GVHD, grade II, III, or IV — no. (%) 5 (10) 10 (5) 0.17
Antifungal prophylaxis — no. (%)¶
Liposomal amphotericin B 49 (96) 177 (82)
Fluconazole 2 (4) 40 (18) 0.02
* CMV denotes cytomegalovirus, and GVHD graft-versus-host disease.
† P values were calculated by Fisher’s exact probability t-test, or by Student’s t-test for continuous variables.
‡ Recipients of transplants from mismatched related donors received rabbit antithymocyte globulin as part of their pre-
transplantation conditioning regimen.
§ Neutropenia was defined as 0.1×109 neutrophils per liter or less.
¶ Antifungal prophylaxis consisted of fluconazole for standard-risk patients and liposomal amphotericin B for high-risk 
patients. At the time of allogeneic hematopoietic stem-cell transplantation, patients were considered to be at high risk 
for invasive fungal disease if they were receiving a transplant from an HLA-mismatched related donor or if they were re-
ceiving a transplant from an HLA-identical sibling and had undergone conditioning that included total-body irradiation. 
Patients were considered to be at standard risk if they were receiving a transplant from an HLA-identical sibling and 
had not undergone conditioning with total-body irradiation.
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cumulative incidence method, and PTX3 status 
among patients with and those without infection 
was compared with the use of Gray’s test.20 Cu-
mulative incidences were computed with R soft-
ware, version 2.10.1 (cmprsk package),21 with 
censoring of data at the date of the last follow-up 
visit, and with relapse and death as competing 
risks. A period of 24 months was chosen to in-
clude all cases in the discovery cohort. Overall 
survival, defined as the time from transplanta-
tion to death from any cause, was estimated with 
the use of the Kaplan–Meier method and assessed 
according to PTX3 status with the use of the log-
rank test. Additional details on statistical meth-
ods are provided in the Supplementary Appendix.
R esult s
Genetic Variants in Donor PTX3 and the Risk 
of Invasive Aspergillosis
The PTX3 gene was analyzed for 22 SNPs span-
ning approximately 25 kb on chromosome 3 (Ta-
ble S2 in the Supplementary Appendix). We as-
sessed the risk of invasive aspergillosis according 
to recipient or donor PTX3 genotypes by estimat-
ing the cumulative incidence of infection among 
transplant recipients 24 months after transplan-
tation. Several SNPs in the donors were associ-
ated with a risk of invasive aspergillosis in the 
recipients. We did not observe an association be-
tween SNPs in recipients and a risk of infection 
(Table S3 in the Supplementary Appendix). Among 
these SNPs, only +281A/G, +734A/C (D48A), and 
+1449A/G remained significantly associated with 
invasive aspergillosis after correction for multi-
ple testing. The cumulative incidence of invasive 
aspergillosis among patients with +281A/G and 
+1449A/G was 37% for genotype GG and 14% for 
genotypes AA and AG combined (P<0.001; ad-
justed P = 0.002) (Fig. 1A); the cumulative inci-
dence of invasive aspergillosis among patients 
with +734A/C was 34% for genotype AA and 14% 
for genotypes AC and CC combined (P<0.001; ad-
justed P = 0.005) (Fig. 1B).
Analysis of linkage disequilibrium between 
markers showed the existence of three distinct 
linkage-disequilibrium blocks (Fig. S1 in the 
Supplementary Appendix). Haplotype analysis 
revealed that an absence of donor haplotypes T-A 
(block 1), A-A (block 2), and A-C (block 3) was 
associated with an increased risk of infection 
among recipients after transplantation (Table S4 
in the Supplementary Appendix), even though the 
cumulative incidence of infection among patients 
with A-C/A-C (block 1) donors was not signifi-
cantly different from the incidence among patients 
with T-A/T-A donors and the cumulative incidence 
of infection among patients with T-G/T-G (block 2) 
donors was not significantly different from the 
incidence among patients with A-A/A-A donors 
(Fig. S2 in the Supplementary Appendix). How-
ever, the cumulative incidence of infection with 
transplants from G-A/G-A (hereafter referred to 
as h2/h2) block 3 donors was significantly 
higher than that with transplants from A-C/A-C 
(h1/h1) donors and A-C/G-A (h1/h2) donors (37% 
Figure 1 (facing page). Cumulative Incidence of Invasive 
Aspergillosis and Estimated Overall Survival after Hema-
topoietic Stem-Cell Transplantation in 268 Patients in 
the Discovery Cohort, According to Donor PTX3 Variants.
Panels A, B, C, and D show the probability of proven or 
probable invasive aspergillosis, with censoring of data 
at 24 months and with relapse and death as competing 
events. P values were calculated with the use of Gray’s 
test. Panel E shows the probability of overall survival, 
with censoring of data at 30 months. Kaplan–Meier 
 estimates were used to calculate survival curves, and 
P values were determined with the use of the log-rank 
test. Panel A shows the cumulative incidence of inva-
sive aspergillosis in transplant recipients according to 
donor +281A/G genotypes. The same plot also shows 
donor +1449A/G, since it displayed complete linkage 
disequilibrium (r 2=1) with +281A/G among cases of 
 invasive aspergillosis. Panel B shows the cumulative 
incidence of invasive aspergillosis according to donor 
+734A/C (D48A) genotypes. Panel C shows the cumu-
lative incidence of invasive aspergillosis according to 
donor haplotypes h1/h1 (A-C/A-C), h1/h2 (A-C/G-A), 
and h2/h2 (G-A/G-A). The +281A/G and +1449A/G 
SNPs are in strong linkage disequilibrium and can be 
used interchangeably within haplotype block 3. Panel D 
shows the cumulative incidence of invasive aspergillo-
sis according to donor haplotypes (h1/h1, as well as 
h1/h2 and h2/h2) and type of donor (HLA-matched re-
lated donor [MRD] or HLA-mismatched related donor 
[MMRD]). Haplotypes h1/h1 and h1/h2 were combined 
in a single category, since they conferred a similar risk 
of invasive aspergillosis, as shown in Panel C. P = 0.75 
for the test for interaction between the PTX3 haplo-
types and the type of transplant. Panel E shows overall 
survival according to donor PTX3 variants. Shown are 
the results for patients who received transplants from 
MRDs with the h1/h1 or h1/h2 haplotype versus pa-
tients who received transplants from other donors 
(MMRDs with the h1/h1 or h1/h2 haplotype and either 
MRDs or MMRDs with the h2/h2 haplotype).
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vs. 15% and 37% vs. 14%, respectively; P<0.001; 
adjusted P = 0.001); the cumulative incidence of 
infection with transplants from A-C/G-A (h1/h2) 
donors was similar to that with transplants from 
A-C/A-C (h1/h1) donors (P = 0.87) (Fig. 1C).
With regard to rare haplotypes, an 18% inci-
dence of invasive aspergillosis was observed 
among recipients of transplants from A-A/A-A 
donors (P = 0.85), whereas no cases were observed 
among recipients of transplants from donors 
with the A-C/A-A haplotype (P = 0.31) (Fig. S3 in 
the Supplementary Appendix).
In the final multivariate SNP models, the 
adjusted hazard ratio for invasive aspergillosis 
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with either donor genotype +281GG or donor 
genotype +1449GG was 2.92 (95% confidence 
interval [CI], 1.69 to 5.05; P<0.001), and the haz-
ard ratio with donor genotype +734AA was 2.62 
(95% CI, 1.52 to 4.54; P<0.001) (Table 2). In the 
final haplotype model, the hazard ratio for inva-
sive aspergillosis with h2/h2 carriage was 3.08 
(95% CI, 1.47 to 6.44; P = 0.003). Risk estimates 
were similar when patients with “possible” (as 
opposed to “probable” or “proven”) aspergillosis 
were excluded and when patients with invasive 
fungal disease other than invasive aspergillosis 
were included (Fig. S4 in the Supplementary Ap-
pendix).
The characteristics of the patients in the con-
firmation case–control study were similar to 
those of the patients in the initial study (Table 
S1 in the Supplementary Appendix), but the con-
firmation study included recipients of transplants 
from related donors and recipients of trans-
plants from unrelated donors. Haplotype fre-
quencies in the confirmation population were 
similar to those in the discovery population 
(Table S5 in the Supplementary Appendix). The 
significant association between donor haplotype 
h2/h2 and the risk of invasive aspergillosis in the 
discovery study (T-cell–depleted grafts and ab-
sence of GVHD and its prophylaxis) was also 
observed in the confirmation study (T-cell– 
repleted grafts and presence of GVHD and use 
of prophylaxis) (adjusted odds ratio, 2.78; 95% 
CI, 1.22 to 8.93; P = 0.03) (Table 2) but not in a 
second, independent confirmation study involv-
ing a cohort of patients with prolonged neutro-
penia who had not undergone HSCT (Table S6 in 
the Supplementary Appendix).
Risk of Invasive Aspergillosis According to 
Donor Haplotype and HLA-Matching Status
Given that donor PTX3 haplotypes and HLA pro-
file are pretransplantation predictors of the risk 
of invasive aspergillosis, we stratified patients in 
the discovery cohort according to the type of 
donor (HLA-matched related donor vs. HLA-mis-
matched related donor) and haplotype (h2/h2 vs. 
h1/h1 or h1/h2). Among transplant recipients 
whose donors had the h1/h1 or h1/h2 haplotype, 
the cumulative incidence of invasive aspergillosis 
increased from 8% among recipients with matched 
related donors to 19% among those with mis-
matched related donors (P = 0.02) (Fig. 1D). How-
ever, in the presence of the h2/h2 haplotype, the 
risk increased further, from 30% among recipi-
ents with matched related donors (P = 0.005 for 
the comparison with h1/h1 or h1/h2 matched 
related donors) to 41% among those with mis-
matched related donors (P<0.001 for the com-
parison with h1/h1 or h1/h2 matched related do-
nors). In a multivariate analysis, the hazard ratio 
for invasive aspergillosis among transplant re-
Table 2. Multivariate Analysis of the Association of Donor PTX3 Variants with the Risk of Invasive Aspergillosis  
among Transplant Recipients in the Discovery and Confirmation Studies.*
Donor PTX3 Variant Discovery Study (N = 268) Confirmation Study (N = 330)
Adjusted Hazard Ratio 
(95% CI)† P Value
Adjusted Odds Ratio 
(95% CI)‡ P Value
+281A/G SNP, GG genotype 2.92 (1.69–5.05) <0.001 2.14 (1.20–3.80) 0.01
+734A/C SNP, AA genotype 2.62 (1.52–4.54) <0.001 1.92 (0.91–3.04) 0.07
Haplotype h2/h2 3.08 (1.47–6.44) 0.003 2.78 (1.22–8.93) 0.03
* CI denotes confidence interval, and SNP single-nucleotide polymorphism. Multivariate analyses were based on the sub-
distribution regression model of Fine and Gray22 in the discovery study and on conditional logistic regression in the 
confirmation study. In the SNP model, the genetic variants were computed one at a time with the clinical covariates. 
The results for donor +281GG genotype are identical to those obtained for the +1449GG genotype because of their 
complete linkage disequilibrium among cases of invasive aspergillosis. The combination of genotypes AA and AG was 
the reference category for +281A/G, and the combination of genotypes CC and CA was the reference category for 
+734A/C. For the haplotype model, the reference category was h1/h1. Hazard ratios and odds ratios are for the pres-
ence versus the absence of the genotype or haplotype that confers a risk of invasive aspergillosis.
† Hazard ratios have been adjusted for HLA-matching status, use or nonuse of total-body irradiation in the myeloablative 
conditioning, and antifungal prophylaxis (fluconazole or liposomal amphotericin B). The only clinical variable that re-
mained significantly associated with invasive aspergillosis in the SNP and haplotype models was receipt of a transplant 
from an HLA-mismatched relative (+281A/G: hazard ratio, 1.94; 95% CI, 1.07 to 3.52; P = 0.03; +734A/C: hazard ratio, 
1.88; 95% CI, 1.04 to 3.42; P = 0.04; haplotype h2/h2: hazard ratio, 1.95; 95% CI, 1.06 to 3.58; P = 0.03).
‡ Odds ratios have been adjusted for HLA-matching status and use or nonuse of total-body irradiation in the myeloabla-
tive conditioning regimen.
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cipients with h1/h1 or h1/h2 mismatched related 
donors versus those with matched related donors 
was 2.46 (95% CI, 1.10 to 5.50; P = 0.03). Among 
transplant recipients with h2/h2 donors, the haz-
ard ratio, with h1/h1 or h1/h2 matched related 
donors as the reference group, was further in-
creased, from 3.96 (95% CI, 1.49 to 10.50; 
P = 0.006) among recipients with matched related 
donors to 6.02 (95% CI, 2.58 to 14.00; P<0.001) 
among those with mismatched related donors. 
Accordingly, the probability of survival at 30 months 
after transplantation decreased from 63% among 
patients who received transplants from matched 
related donors with haplotype h1/h1 or h1/h2 to 
37% among patients who received transplants 
from either h1/h1 or h1/h2 mismatched related 
donors or from h2/h2 matched or mismatched 
related donors (P = 0.01) (Fig. 1E).
Effect of the +734A/C SNP on PTX3 Messenger 
RNA Folding
To determine the molecular consequences of the 
SNPs in PTX3 haplotype block 3, we examined 
the pathogenic potential of each SNP in terms of 
protein function. We first compared the amino 
acid sequence of annotated PTX3 proteins among 
several mammals to determine whether the 
+734A/C (D48A) mutation was occurring in a 
phylogenetically conserved site. Alignment of 
PTX3 sequences confirmed that the D48A substi-
tution leading to an alanine residue in humans 
lies in an evolutionarily conserved region within 
the mammalian lineage, since all other species 
carried an aspartic acid residue instead (Fig. S5 
in the Supplementary Appendix). Even though 
this mutation affected a conserved site, it was 
nonetheless predicted in silico as benign with re-
spect to protein folding and structural stability. 
More important, when we looked at models of 
the effect of the +734A/C SNP on PTX3 messen-
ger RNA (mRNA) folding, we found it to be se-
verely affected by the nucleotide substitution 
(Fig. S6 in the Supplementary Appendix), indicat-
ing altered mRNA stability. No differences in 
splicing were predicted for intronic SNPs (Table 
S7 in the Supplementary Appendix).
Decreased Expression of PTX3 with the h2/h2 
Haplotype
To assess the functional consequences of h2/h2, 
we compared PTX3 expression in vivo in the lungs 
of transplant recipients with invasive aspergillosis 
and in those without invasive aspergillosis, as 
well as in vitro on purified cells. We found higher 
levels of PTX3 in bronchoalveolar-lavage fluid, but 
not in plasma (Fig. S7 in the Supplementary Ap-
pendix), from patients with invasive aspergillosis 
than in patients without invasive aspergillosis 
(Fig. 2A). More important, median (±SD) PTX3 
levels in bronchoalveolar-lavage fluid differed sig-
nificantly according to donor haplotype both for 
patients with invasive aspergillosis (2.50±0.73 ng 
per milliliter for h1/h1 [14 patients] vs. 1.36±0.14 ng 
per milliliter for h2/h2 [15 patients]; P<0.001) 
and for those without invasive aspergillosis 
(0.83±0.06 ng per milliliter for h1/h1 [21 patients] 
vs. 0.47±0.03 ng per milliliter for h2/h2 [21 pa-
tients]; P<0.001). Further supporting these find-
ings, immunofluorescence analysis of lung-biopsy 
specimens from patients with invasive aspergil-
losis revealed decreased positivity for PTX3 in 
lung tissue from transplant recipients with h2/h2 
donors (4 patients) as compared with transplant 
recipients with h1/h1 donors (5 patients) (Fig. 2B).
We performed in vitro assessment of mRNA 
and protein expression in purified peripheral-
blood neutrophils, one major cell type express-
ing PTX3. Mature neutrophils do not contain 
detectable levels of PTX3 mRNA.7 In contrast, 
neutrophil precursors (most notably promyelo-
cytes, as well as myelocytes plus metamyelocytes) 
express PTX3 transcript.7 The h2/h2 haplotype 
was correlated with lower levels of PTX3 mRNA 
in h2/h2 precursors than in h1/h1 precursors 
(3 donors for each haplotype) (Fig. 2C). Analysis 
of intracellular protein levels revealed that PTX3 
was constitutively present in resting neutrophils, 
although protein levels were markedly lower in 
h2/h2 neutrophils (in 14 patients) than in h1/h1 
neutrophils (in 12 patients) (Fig. 2D). Defective 
expression of intracellular PTX3 in h2/h2 neutro-
phils as compared with h1/h1 neutrophils (8 pa-
tients for each haplotype) was confirmed by 
means of Western blotting (Fig. 2E) and immuno-
fluorescence (Fig. 2F).
Antifungal Capacity of Neutrophils  
and the h2/h2 Haplotype
To ascertain the functional consequences of the 
h2/h2 haplotype on antifungal effector mecha-
nisms, we investigated the effector capacity of 
neutrophils bearing distinct haplotypes. Neutro-
phils from h2/h2 patients showed a significantly 
impaired ability to phagocytose conidia of A. fumig-
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atus, with a 40-percentage-point reduction, as 
compared with h1/h1 cells (Fig. 3A). Moreover, 
h2/h2 neutrophils also showed a 20-percentage-
point decrease in their conidiocidal activity in 
general, as compared with h1/h1 cells (Fig. 3B). 
Since PTX3 haplotype block 3 underlies two dis-
tinct forms of PTX3 on the basis of the D48A 
substitution (48D and 48A), we assessed whether 
the overall defective antifungal activity displayed 
by h2/h2 neutrophils was linked to an altered 
ability of either form to bind conidia. However, 
both forms efficiently bound to the fungus, as 
assessed with the use of fluorescence-labeled 
PTX3 (Fig. 3C).
Given that exogenous PTX3 restores antifun-
gal effector mechanisms in PTX3-deficient cells,3,8 
we analyzed whether the addition of PTX3 re-
versed the antifungal effector deficiencies ob-
served in h2/h2 neutrophils. The addition of 
either form of PTX3 significantly enhanced 
phagocytosis of conidia by h2/h2 neutrophils 
(63% for 48D, and 57% for 48A) and h1/h1 neu-
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trophils (80% for 48D and 73% for 48A) (Fig. 
3D). The phagocytic activity of h2/h2 neutrophils 
was further improved on preopsonization of 
conidia with either form of PTX3, since these 
cells were able to internalize conidia even more 
efficiently (82% for 48D, and 80% for 48A). 
Similarly, the conidiocidal activity of h2/h2 neu-
trophils was restored to 62% by the direct addi-
tion of 48D and to 50% by the direct addition of 
48A, as well as to 60% after preopsonization of 
conidia with 48D and to 57% after preopsoniza-
tion of conidia with 48A (Fig. 3E).
Discussion
In this study, we found an association between 
donor h2/h2 haplotype in PTX3 and invasive as-
pergillosis in patients undergoing HSCT, a find-
ing that supports the nonredundant role of PTX3 
in host defense against A. fumigatus.3,4,7 More im-
portant, the increased risk of infection was ob-
served regardless of the HLA-matching status of 
the donor, T-cell manipulation, and acute GVHD 
and prophylaxis, further sustaining a potentially 
independent contribution of PTX3 variants to the 
development and outcome of invasive aspergillo-
sis in the context of various strategies for modu-
lating lymphocyte function.
PTX3 SNPs have been shown to modify the 
risk of pulmonary tuberculosis23 and colonization 
by Pseudomonas aeruginosa in patients with cystic 
fibrosis.24 Furthermore, these SNPs were found 
to alter blood levels of the PTX3 protein in Gha-
naian women25 and in lung-transplant recipients 
with primary graft dysfunction.26 In our study, 
the h2/h2 haplotype was consistently associated 
with a defect in PTX3 expression in broncho-
alveolar-lavage fluid, lung-biopsy specimens, and 
innate immune cells. This association was not 
confirmed systemically, a finding that suggests 
a requirement for the presence of PTX3 on the 
infected lung, where it opsonizes the fungus and 
helps to resolve infection.
Although neutropenia is an important risk 
factor for opportunistic fungal infections, most 
cases of aspergillosis in patients who have un-
dergone allogeneic HSCT occur a few months 
after transplantation, when neutrophil levels have 
returned to the normal range, suggesting that 
neutrophils, which express PTX3 and are required 
for resistance to A. fumigatus,7 may be particularly 
relevant for the observed susceptibility pheno-
type. Indeed, PTX3 SNPs were not associated 
with invasive aspergillosis in patients with pro-
longed neutropenia who did not undergo trans-
plantation, supporting the importance of the 
PTX3 defect in neutrophils. Because PTX3 has a 
role as an opsonin, limiting the amount of PTX3 
available to bind the fungus most likely restrains 
the efficiency of phagocytosis and fungal clear-
ance, as was observed for h2/h2 neutrophils. The 
exogenous addition of PTX3 to PTX3-deficient 
neutrophils reversed the functional deficit, con-
firming that the innate antifungal mechanisms 
Figure 2 (facing page). Effect of the h2/h2 Haplotype 
on PTX3 Expression.
Panel A shows PTX3 levels in samples of broncho-
alveolar-lavage fluid (BAL) from patients with proven 
or probable invasive aspergillosis (IA) and those with-
out IA whose donors had h1/h1 (A-C/A-C) (14 patients 
with IA and 21 without IA) or h2/h2 (G-A/G-A) (15 pa-
tients with IA and 21 without IA). Shown are median 
(±SD) levels (horizontal lines within the boxes) and in-
terquartile ranges (lines above and below the boxes), 
assessed in duplicate. P values were calculated with 
the use of the two-tailed Mann–Whitney rank-sum test. 
Panel B shows immunofluorescence staining of lung-
biopsy specimens with antihuman PTX3 as the primary 
antibody and antirabbit tetramethylrhodamine isothiocy-
anate as the secondary antibody. DAPI (4′,6-diamidino-
2-phenylindole) was used to counterstain tissues. Im-
ages are representative of at least four samples for each 
haplotype assessed in two distinct preparations. Scale 
bars indicate 100 µm. Panel C shows analysis of PTX3 
mRNA expression in promyelocytes (PM) and myelo-
cytes plus metamyelocytes (MY). Shown is the mean 
(±SD) messenger RNA (mRNA) level in three bone 
marrow donors for each haplotype, assessed in tripli-
cate. Panel D shows PTX3 levels in neutrophils as as-
sessed by enzyme-linked immunosorbent assay. Shown 
is the mean (±SD) protein level in at least 12 patients 
for each donor haplotype, assessed in duplicate. In 
Panels C and D, P values were calculated with the use 
of an unpaired Student’s t-test with Bonferroni’s ad-
justment. Panel E shows Western blot analysis of PTX3 
expression in neutrophils. Blots of cell lysates were in-
cubated with a polyclonal antibody against PTX3, and 
normalization was performed with an antihuman 
β-tubulin antibody. Panel F shows immunofluores-
cence imaging of PTX3 in neutrophils. Neutrophils 
were incubated with a primary antibody against PTX3, 
followed by a secondary fluorescein isothiocyanate 
(FITC)–conjugated antirabbit IgG antibody. Nuclei were 
counterstained with DAPI. Scale bars indicate 100 µm. 
The findings in Panels E and F are representative of 
those in at least eight patients tested for each haplo-
type combination, assessed in triplicate.
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Figure 3. Antifungal Activity of Neutrophils According to the PTX3 h2/h2 Haplotype.
Neutrophils were isolated from peripheral-blood specimens from transplant recipients whose donors had PTX3 
haplotypes h1/h1 (A-C/A-C) or h2/h2 (G-A/G-A). For the data shown in Panels A, B, D, and E, neutrophils were cul-
tured in the presence of Aspergillus fumigatus conidia at a cell:fungus ratio of 1:1. Where indicated, data were ob-
tained with the use of recombinant forms of human PTX3 bearing either an aspartic acid (48D) or an alanine (48A) 
at amino acid position 48. Panel A shows phagocytosis efficiency (expressed as a percentage of conidia internaliza-
tion) of unopsonized conidia of A. fumigatus. Phagocytosis was quantified with the use of fluorescence microscopy 
of ingested FITC-labeled conidia. Shown are representative microscopic images. Panel B shows conidiocidal activity 
of neutrophils (expressed as a percentage of colony-forming-unit [CFU] inhibition) on unopsonized conidia of A. fu-
migatus. Panel C shows the interaction of PTX3 48D and 48A with viable conidia of A. fumigatus. Binding was as-
sessed by analysis of Alexa Fluor 488 fluorescence by means of a fluorescence-activated cell sorter and fluorescence 
microscopy. Fluorescence microscopy was performed on conidia stained with calcofluor white (a chitin-specific dye) 
and incubated with Alexa Fluor 488–labeled PTX3. Representative histograms and images are shown. Panel D 
shows phagocytosis efficiency (expressed as a percentage of conidia internalization) and Panel E shows conidiocidal 
activity (expressed as a percentage of CFU inhibition) in the presence of PTX3 48D and 48A or conidia preopsonized 
with 48D and 48A (opsPTX3). In Panels A, B, D and E, mean (±SD) values are shown for at least 12 different pa-
tients for each haplotype, assessed in triplicate. P values were calculated with the use of an unpaired Student’s t-test 
with Bonferroni’s adjustment.
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of these cells are compromised by a lack of suf-
ficient PTX3 to effectively counter the fungus. 
Our observation that both 48A and 48D forms of 
PTX3 bound conidia efficiently further supports 
a deficiency of PTX3 in quantity, not in quality. 
It is also possible that PTX3 deficiency adversely 
affects antifungal mechanisms mediated by other 
innate immune receptors27 or leukocyte recruit-
ment in the lungs.28
Whatever the mechanism (or mechanisms), 
the absence of an association between genetic 
variants in transplant recipients and invasive 
aspergillosis suggests that epithelial PTX3 has a 
smaller role, if any, in the immune response to 
the fungus. PTX3 expression was not detectable 
in epithelial cells stimulated with A. fumigatus 
conidia,3 even though its induction by proinflam-
matory stimuli in human lung epithelial cells 
has been documented.29 Exogenous Ptx3 has 
been found to drive innate antifungal resistance 
of epithelial cells through defensins and enhance-
ment of fungal phagocytosis,8 suggesting that 
myeloid PTX3 may nonetheless play an impor-
tant part in regulating epithelial antifungal 
mechanisms. It will be important to determine 
whether PTX3 deficiency also affects the initia-
tion and skewing of adaptive immune responses 
to the fungus, as shown in Ptx3-deficient mu-
rine dendritic cells.3
Mechanistically, the decreased expression of 
PTX3 transcript in neutrophil precursors is con-
sistent with the predicted alterations in the 
mRNA secondary structure, suggesting that the 
+734A/C nucleotide change most likely affects 
regulation of PTX3 expression. Also, a contribu-
tion of the intronic SNPs from the h2/h2 haplo-
type or other SNPs in the 5′ region to the ob-
served phenotype cannot be ruled out. However, 
even though no alterations in PTX3 structure 
were identified as a consequence of the D48A 
substitution, damage to its electrostatic poten-
tial or interactions with other proteins also can-
not be ruled out. The fact that the adjacent posi-
tions 47 and 49 encode cysteine residues involved 
in the formation of PTX3 protein complex octam-
ers30 supports this possibility.
In conclusion, we found that genetic defi-
ciency of PTX3 affects the antifungal function of 
neutrophils. This deficiency may increase sus-
ceptibility to invasive aspergillosis in patients 
undergoing HSCT.
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